Uni-Bio Science Group Limited

Equities

690

KYG9198H1406

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.08 HKD +3.90% Intraday chart for Uni-Bio Science Group Limited -2.44% +11.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Uni-Bio Science's Profit to Climb in 2023 MT
Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
Chinese Regulator NMPA Accepts Uni-Bio's Marketing Application for Eye Drops MT
Uni-Bio Science Group Limited Announces the Acceptance of its Marketing Application for Diquafosol Sodium Eye Drops by the China National Medical Products Administration CI
China Grants Uni-Bio Science's Injection for Orthopedic Diseases MT
Uni-Bio Science Group Limited Announces Approval of Marketing Application of Bogutai (Teriparatide Injection) by the China National Medical Products Administration CI
Uni-Bio Science Group Limited commences an Equity Buyback for 636,476,815 shares, representing 10% of its issued share capital, under the authorization approved on May 19, 2023. CI
Uni-Bio Science Group Limited Announces the Resignation of Ms. Zhang Yanfen as Executive Director CI
Uni-Bio Science's Unit Grants 7.2 Million Yuan Loan to Taili Biomedical Technology MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director CI
Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Uni-Bio Science Group Limited Provides Financial Guidance for the Year Ended 31 December 2022 CI
Uni-Bio Science Unit Renews Property Lease for Two Years MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Uni-Bio Science Group Limited Announces Marketing Application of Bogutai (Teriparatide Injection) Officially Accepted by the China National Medical Products Administration CI
Uni-Bio Science CFO Resigns MT
Uni-Bio Science Group Limited Announces Resignation of She Shi Bin Richard as Chief Financial Officer CI
Uni-Bio Science Group Limited Announces Executive Changes CI
Uni-Bio Science Narrows Loss on Higher Core Drugs Sales in 2021; Shares Rise 3% MT
Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Uni-Bio Science Arm Signs R&D Deal for Medical Aesthetics Materials Development MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021 CI
Chart Uni-Bio Science Group Limited
More charts
Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
More about the company

Annual profits - Rate of surprise